Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Cash Flow (2016 - 2026)

Ocular Therapeutix has reported Net Cash Flow over the past 14 years, most recently at -$70.4 million for Q1 2026.

  • For Q1 2026, Net Cash Flow fell 65.86% year-over-year to -$70.4 million; the TTM value through Mar 2026 reached $317.0 million, up 337.72%, while the annual FY2025 figure was $345.0 million, 75.87% up from the prior year.
  • Net Cash Flow for Q1 2026 was -$70.4 million at Ocular Therapeutix, down from $392.3 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $392.3 million in Q4 2025 and troughed at -$70.4 million in Q1 2026.
  • A 5-year average of $29.6 million and a median of -$18.6 million in 2022 define the central range for Net Cash Flow.
  • On a YoY basis, Net Cash Flow climbed as much as 1333.48% in 2024 and fell as far as 173.89% in 2024.
  • Year by year, Net Cash Flow stood at -$18.6 million in 2022, then surged by 557.14% to $85.3 million in 2023, then crashed by 141.19% to -$35.1 million in 2024, then skyrocketed by 1217.06% to $392.3 million in 2025, then plummeted by 117.94% to -$70.4 million in 2026.
  • Business Quant data shows Net Cash Flow for OCUL at -$70.4 million in Q1 2026, $392.3 million in Q4 2025, and -$46.4 million in Q3 2025.